

syncope to the hormonal alterations along the menstrual cycle (2, 3, 4). Also, the presence of estrogen receptors in the heart, vascular smooth muscle, and autonomic brain stem centers (e.g. nucleus tractus solitarius, ventrolateral medulla) suggest a possible involvement in the regulation of the cardiovascular system (5).

Hormone replacement therapy (HRT) supplements exogenous ovarian hormones to the postmenopausal women where these hormones have decreased in amount. This therapy introduced decades ago for the treatment of postmenopausal symptoms still continues despite a lot of controversies. The purpose of this study was to evaluate the influence of ovarian hormone fluctuations in women as they pass through the various phases of reproductive life and following the use of HRT in postmenopausal women, on cardiac autonomic nervous system (ANS) reflected by parameters of heart rate variability (HRV), E: I ratio, 30:15 ratio and blood pressure (BP) tests. Heart rate variability, that is, the amount of heart rate fluctuations around the mean heart rate is a valuable tool to investigate the ANS. Reduced HRV has been reported to predict increased risk for subsequent mortality of all causes and sudden cardiac death (6). Lower HRV was also proven to be associated with a greater risk for developing hypertension among normotensive men; and hypertension is one of the major risk factors of congestive heart disease (7). Acute myocardial infarctions are accompanied by a decreased HRV, which is due to reduced vagal or increased sympathetic outflow to the heart (8).

In this present study, non-invasive

methods of ANS parameter measurements were practised. A combination of these was employed as some of these tests give information about the cardiac sympathetic functions (postural challenge test, sustained handgrip test) whereas others give information about the cardiac parasympathetic functions (basal heart rate variability, E:I ratio, 30:15 ratio) (9)

MATERIALS AND METHODS

The study was conducted in the Department of Physiology, University College of Medical Sciences and GTB Hospital, Delhi. The ethical committee of the institution cleared the project. The subjects were informed about the project both in written and in person and written consent was obtained from all subjects. The study included 90 adult female subjects. The postmenopausal subjects were recruited from the HRT clinic of Department of Obstetrics and Gynaecology, GTB hospital. All the postmenopausal women included had cessation of menstruation atleast one year before. The premenopausal women were recruited from the relatives of the postmenopausal women attending the HRT clinic. Subjects on oral contraceptive pills and drugs that alter the cardiovascular functions were also excluded from the study. All those women with history of diabetes mellitus, hypertension, heart disease, history of smoking and alcoholism were excluded. There were the following groups :

Group I (n=30): Premenopausal women in the age group of 30 to 45 years having a regular menstrual cycle. The subjects in the Group I were investigated twice :

Group 1A In proliferative phase of menstrual cycle

Group 1B In secretory phase of menstrual cycle

Group 2 (n=30): Postmenopausal women in age group of 45 to 55 years who had not yet been put on HRT.

Group 3 (n=30): Postmenopausal women in age group of 45 to 55 years on HRT who were on oral HRT for the last three months or more in the form of continuous combined regimen. (conjugated equine estrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg daily).

Experimental protocol

All the subjects were tested under similar laboratory conditions. The tests were conducted according to the recommended protocol used in clinical studies (10, 11). The subjects abstained from coffee, tea or cola for 12 hours before the measurement. A light breakfast was allowed 2 hours before the study. All the measurements were performed between 10.30 am to 12.30 pm in an isolated examination room the temperature of which was maintained between 25°C and 27°C. They were allowed to get familiar with the experimental and environmental condition of the laboratory and procedures were explained to them. For time domain analysis of HRV, E:1 ratio and 30:15 ratio lead-II EGG was recorded using the student physiograph machine (INCO), while Postural Challenge Test and Sustained Handgrip Test were performed using a mercury sphygmomanometer by the standard Riva-Roci method.

Statistical Analysis: All the results were obtained by SPSS-13 for windows using one-way ANOVA followed by Tukey test at 5% level of significance.

RESULTS

The age (in years) and BMI (in kg/m²) in mean±SD of groups were: Group 1 (premenopausal women) age 33.83±2.44 and BMI 21.28±2.78, Group 2 (postmenopausal women) age 51.03±3.28 and BMI 24.73±3.12, Group 3 (postmenopausal women on HRT) age 52.53±2.87 and BMI 24.33±2.31.

Table I shows the cardiac autonomic activity of Group 2 (postmenopausal women), Group 1A (premenopausal women in proliferative phase of menstrual cycle) and Group 1B (premenopausal women in secretory phase of menstrual cycle) and their intercomparison. BHRV, E:1 ratio & 30:15 ratio was significantly lower in postmenopausal women (Group 2) as compared to premenopausal women both in the proliferative phase (Group 1A) and secretory phase (Group 1B). BHRV, E:1 ratio and 30:15 ratio were significantly higher in secretory phase (Group 1B) compared to proliferative phase (Group 1A). The basal systolic and diastolic blood pressures were significantly higher in postmenopausal women (Group 2) compared to proliferative phase (Group 1A) & secretory phase (Group 1B). There were no significant difference in basal BP between Group 1A & 1B. The changes in systolic BP in postural challenge test and changes in diastolic BP in sustained handgrip test were insignificant.

Table II shows the comparison of cardiac autonomic activity of postmenopausal women

TABLE I: Showing cardiac autonomic activity of Group 1A (premenopausal women in proliferative phase), Group 1B (premenopausal women in secretory phase), & Group 2 (postmenopausal women).

<i>Parameters</i>	<i>Group 1A Mean±SD</i>	<i>Group 2 Mean±SD</i>	<i>Tukey test (group 1A & 2) P value</i>	<i>Group 1B Mean±SD</i>	<i>Tukey test (group 1B & 2) P value</i>	<i>Tukey test (group 1A & 1B) P value</i>
BHRV (beat/min)	16.57±5.52	11.13±3.50	<0.001	20.50±4.22	<0.001	0.009
E:l Ratio	1.34±0.14	1.18±0.07	<0.001	1.42±0.12	<0.001	0.047
30:15 Ratio	1.25±0.14	1.15±0.10	0.037	1.34±0.16	<0.001	0.046
SSBP (mm Hg)	111.2±6.27	124.2±6.88	<0.001	111.07±5.55	<0.001	1.00
SDBP (mm Hg)	73.13±4.51	83.33±5.93	<0.001	74.27±5.80	<0.001	0.833
CSBP (mm Hg)	4.33±4.36	4.27±5.08	1.000	3.67±4.20	0.954	0.938
CDBP (mm Hg)	27.00±4.66	23.47±4.33	0.110	25.60±8.01	0.519	0.804

SSBP – supine systolic BP, SDBP – supine diastolic BP, CSBP – change in systolic BP in postural challenge test, CDBP – change in diastolic BP in sustained handgrip test.

TABLE II: Showing cardiac autonomic activity of Group 2 (postmenopausal women) and Group 3 (postmenopausal women on HRT).

<i>Parameters</i>	<i>Group 2 Mean±SD</i>	<i>Group 3 Mean±SD</i>	<i>Tukey test (Group 2 & 3) P-value</i>
BHRV (beats/min)	11.13±3.50	17.43±5.39	<0.001
E:l Ratio	1.18±0.07	1.26±0.10	0.018
30:15 Ratio	1.15±0.10	1.25±0.14	0.032
SSBP (mm Hg)	124.2±6.88	115.33±7.07	<0.001
SDBP (mm Hg)	83.33±5.93	76.4±4.34	<0.001
CSBP (mm Hg)	4.27±5.08	3.47±4.07	0.898
CDBP (mm Hg)	23.47±4.33	26.13±6.34	0.32

SSBP – supine systolic BP, SDBP – supine diastolic BP, CSBP – change in systolic BP in postural challenge test, CDBP – change in diastolic BP in sustained handgrip test.

(Group 2) & postmenopausal women on HRT (Group 3). BHRV, E:l ratio and 30:15 ratio were significantly higher in postmenopausal women on HRT compared to the other postmenopausal women. Values of supine systolic and diastolic BP were significantly higher in Group 2 compared to Group 3 while the changes in systolic BP in postural challenge test and changes in diastolic BP in sustained handgrip test were insignificant.

DISCUSSION

In this study the age of postmenopausal women was kept in the range of early menopausal years. The premenopausal women were kept in the age group of 30-45 years to make them more comparable to postmenopausal women. Still, the comparison of parameters between premenopausal and postmenopausal women reflects the affect of sex hormones as well as age. However, the

postmenopausal women on HRT are in the same age range as the postmenopausal women without HRT and thus the comparison between postmenopausal women with or without HRT reflects only the variation in the level of female gonadal hormones.

High frequency oscillations in HRV (HF, 0.15–0.40 Hz), which are related to respiration, provide a marker of vagal input to the heart. Low frequency oscillations (LF, 0.04–0.15 Hz) reflect the fluctuations in sympathetic tone and LF/HF ratio (0.01–0.40 Hz) is a marker of sympathovagal balance (12). In time domain, standard deviation of normal RR intervals (SDNN) and root mean square of differences of successive normal RR intervals (rMSSD) are believed to be expression of vagal tone (13). According to Conny, HRV can be assessed in two ways: by calculation of indices based on statistical operation on R-R intervals (time domain) or by spectral (frequency domain) analysis of an array of R-R intervals. These analysis can be performed on short ECG segments (lasting from 0.5 to 5 minutes) or on 24 hour ECG recordings (14).

BHRV, E:I ratio & 30:15 ratio which reflect the parasympathetic tone found significantly lower values in postmenopausal women compared to premenopausal women. (Table I) This can be attributed to increased age and decreased sex hormones in postmenopausal women. We have not come across any study that has used 30:15 ratio and E: I ratio to compare the autonomic status of pre and postmenopausal women. In a previous study of HRV in pre and postmenopausal women it was found that total power, HF and LF of HRV were

significantly lower in postmenopausal women suggesting decreased parasympathetic tone (15). In postural challenge test and sustained handgrip test, systolic and diastolic blood pressure of the postmenopausal women showed significantly higher absolute values of BP during baseline supine recording compared to premenopausal women (Table I). These findings suggest an elevated sympathetic tone in postmenopausal women. Similarly, Zanchetti et al found that systolic and diastolic BP is significantly higher in postmenopausal than in the premenopausal and perimenopausal women (16).

Across the menstrual cycle, significantly higher BHRV, E:I ratio & 30:15 ratio was found in secretory phase indicating parasympathetic dominance in secretory phase (Table I). In contrast, Yildirim et al who investigated the power spectral analysis of HRV during menstrual cycle found increased sympathetic activity in luteal phase (17). Mehta et al documented significantly higher systolic BP and increased sympathetic activity in the pre-menstrual phase compared to post-menstrual & menstrual phases; without significant difference in the parasympathetic activity (18). No significant changes were seen in postural challenge test and in sustained handgrip test across the menstrual cycle; indicating that sympathetic activity remains the same across the menstrual cycle (Table I). Similarly, Matsumoto et al who studied the activity of ANS during the menstrual cycle by means of power spectral analysis of HRV found no intramenstrual cycle differences (19). In contrast, Ettinger et al have suggested that during static handgrip exercise, muscle sympathetic nerve activity is increased more during the menstrual phase compared with

the follicular phase of the ovarian cycle (20).

The postmenopausal women on HRT had significantly higher BHRV, E:l & 30:15 ratio compared to postmenopausal women without HRT (Table II); this suggest that parasympathetic tone was higher in the postmenopausal women on HRT. E:l and 30:15 ratio have not been used by previous researchers in studying the effect of HRT. Previous research that compared the effect of HRT found LF/HF ratio and LF normalized unit significantly decreased after HRT with a significant increase in the HF component of HRV (21). However, some other researchers have documented lack of protective cardiovascular effect of HRT (22). The postmenopausal women on HRT had significantly lower values of systolic and diastolic BP compared to postmenopausal women not on HRT (Table II). This suggests that there was lower sympathetic activity

in women on HRT. In normotensive populations, even small reductions in diastolic BP are postulated to prevent incident hypertension, coronary heart disease, and stroke and suggest decreased cardiac risk (23). An earlier study has also shown that elevation of low postmenopausal hormone levels to physiological premenopausal levels by HRT suppresses sympathetic activity (24).

In conclusion this study found that postmenopausal women had alteration in their autonomic status with higher sympathetic and lower vagal tone compared to premenopausal women. In women on HRT, the sympathovagal balance was shifted towards parasympathetic dominance. Across the menstrual cycle, higher parasympathetic activity was seen in the secretory phase while no change was observed in the sympathetic activity in the two phases.

REFERENCES

1. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. *N Engl J Med* 1993; 329: 247-256.
2. Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein et al. The neuropathic postural tachycardia syndrome. *N Engl J Med* 2000; 343: 1008-1014.
3. Jacob G, Robertson D, Mosqueda-Garcia R, Ertl AC, Robertson RM, Biaggioni I. Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system. *Am J Med* 1997; 103: 128-133.
4. Scott RT, Hodgen GD. The ovarian follicle: life cycle of a pelvic clock. *Clin Obstet Gynecol* 1990; 33: 551-562.
5. Perrot-Applanat M. Estrogen receptors in the cardiovascular system. *Steroids* 1996; 61: 212-215.
6. Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL et al. Reduced heart rate variability and mortality risk in an elderly cohort. *The Framingham Heart Study* 1994; 90: 878-883.
7. Singh JP, Larson MG, Tsuji H, Evans JC, O'Donnell CJ, Levy D. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. *Hypertension* 1998; 32: 293-297.
8. Casolo GC, Stroder P, Signorini C, Calzolari F, Zucchini M, Balli E et al. Heart rate variability during the acute phase of myocardial infarction. *Circulation* 1992; 85: 2073-2079.
9. Bannister R. Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. Oxford (UK): Oxford University Press; 1983; p. 371-405.
10. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. *Br Med J* 1982; 285: 916-918.

11. Ewing DJ, Martyn CN, Young RJ et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 1985; 8: 491-498.
12. Malliani A, Pagani M, Lombardi F, Ceruti S. Cardiovascular neural regulation explored in the frequency domain. *Circulation* 1991; 84: 482-492.
13. Wennerblom B, Lurge L, Tygesen H, Vahisalo R, Hjalmarson A. Patients with uncomplicated coronary artery disease have reduced heart rate variability mainly affecting vagal tone. *Heart* 2000; 83: 290-294.
14. Conny MA, van Ravenswaaij-Arts, Louis AA Kollee, Jeroen CW Hopman, Gerard BA Stoeltinga, Herman P Van Geijn. Heart Rate Variability. *Ann Intern Med* 1993; 118: 436-447.
15. Shailaja S Moodithaya, Sandhya T Avadhany. Comparison of cardiac autonomic activity between pre and post menopausal women using heart rate variability. *Indian J Physiol Pharmacol* 2009; 53: 227-234.
16. Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirrelli A, Sega R; SIMONA participants. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. *J Hypertens* 2005; 23: 2269-2276.
17. Yildirim A, Kabakci G, Akgul E, Tokgozoglu L, Oto A. Effects of menstrual cycle on cardiac autonomic innervation as assessed by heart rate variability. *Ann Noninvasive Electrocardiol* 2002; 7: 60-63.
18. Mehta V, Chakrabarty AS. Autonomic functions during different phases of menstrual cycle. *Indian J Physiol Pharmacol* 1993; 37: 56-58.
19. Matsumoto T, Ushiroyama T, Morimura M, Moritani T, Hayashi T, Suzuki T et al. Autonomic nervous system activity in the late luteal phase of eumenorrheic women with premenstrual symptomatology. *J Psychosom Obstet Gynaecol* 2006; 27: 131-139.
20. Ettinger SM, Silber DH, Gray KS, Smith MB, Yang QX, Kunselman AR et al. Effects of the ovarian cycle on sympathetic neural outflow during static exercise. *J Appl Physiol* 1998; 85: 2075-2081.
21. Yildirim A, Kabakci G, Yarali H, Aybar F, Akgul E, Bukulmez O et al. Effects of hormone replacement therapy on heart rate variability in postmenopausal women. *Ann Noninvasive Electrocardiol* 2001; 4: 280-284.
22. Carnethon MR, Anthony MS, Cascio WE, Folsom AR, Rautaharju PM, Liao D et al. Prospective association between hormone replacement therapy, heart rate, and heart rate variability. The Atherosclerosis risk in communities study. *J Clin Epidemiol* 2003; 56: 565-571.
23. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. *Arch Intern Med* 1995; 155: 701-709.
24. Weitz G, Elam M, Born J, Fehm HL, Dodt C. Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. *J Clin Endocrinol Metab* 2001; 86: 344-348.